Who can benefit from postmastectomy radiotherapy among HR+/HER2-T1-2 N1M0 breast cancer patients? - An explainable machine learning mortality prediction based approach
Favorite
Share
More Options
Fullscreen
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
